70 related articles for article (PubMed ID: 7890266)
1. Silent Thyroiditis Associated with Ropeginterferon α-2b in a Patient with Polycythemia Vera.
Kirito K
Intern Med; 2024 Mar; 63(6):843-846. PubMed ID: 37532547
[TBL] [Abstract][Full Text] [Related]
2. Extreme erythrocytosis in a cat reverts after short-term treatment with hydroxyurea and the cat remains healthy for years.
Billström-Saxon J; Giger U
J Am Vet Med Assoc; 2024 May; 262(5):1-3. PubMed ID: 38452480
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Mannargudi MB; Deb S
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1499-1529. PubMed ID: 28624910
[TBL] [Abstract][Full Text] [Related]
4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease.
Litam PP; Landaw SA; Zamkoff KW
Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266
[TBL] [Abstract][Full Text] [Related]
7. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
8. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
Skotnicki AB; Wolska-Smoleń T
Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
[TBL] [Abstract][Full Text] [Related]
9. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]